Posted by Michael Wonder on 11 Nov 2023
Rznomics secures fast track designation from the US FDA for RZ-001
10 November 2023 - Rznomics announced today that it has received fast track designation from the US FDA for RZ-001, for the treatment of patients with glioblastoma.
Rznomics received Phase I/IIa IND approval for RZ-001 from the FDA and the South Korean Ministry of Food and Drug Safety in glioblastoma and the clinical trial will investigate the safety, tolerability, and efficacy of RZ-001 in patients with glioblastoma.
